Genprex (GNPX) EBIT Growth (3y) (2019 - 2025)
Genprex (GNPX) EBIT Growth (3y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 69.02% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 24.14% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 44.54% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 44.34% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -28.30% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 81.27% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -18.82% |
| 10 | Genprex | 1.88 Mn | -13.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 49.90% |
| Dec 31, 2024 | 13.73% |
| Sep 30, 2024 | -7.93% |
| Jun 30, 2024 | -17.80% |
| Mar 31, 2024 | -4.13% |
| Dec 31, 2023 | -4.50% |
| Sep 30, 2023 | -41.00% |
| Jun 30, 2023 | -22.45% |
| Mar 31, 2023 | -18.44% |
| Dec 31, 2022 | -39.43% |
| Sep 30, 2022 | -37.36% |
| Jun 30, 2022 | -15.93% |
| Mar 31, 2022 | -34.74% |
| Dec 31, 2021 | -25.16% |
| Sep 30, 2021 | -16.10% |
| Jun 30, 2021 | 12.91% |
| Mar 31, 2021 | -97.76% |
| Dec 31, 2020 | -98.89% |
| Sep 30, 2020 | -57.19% |
| Jun 30, 2020 | -54.76% |